Quarterly ResultMay 15, 2026, 04:38 PM
Annovis Bio Q1 Net Loss Widens to $(17.6)M; R&D Up 233%
AI Summary
Annovis Bio reported a significant increase in net loss for Q1 2026, reaching $(17.6) million, compared to $(5.5) million in Q1 2025, primarily driven by a 233% surge in research and development expenses. The company's cash and cash equivalents decreased to $14.2 million, and management expressed substantial doubt about its ability to continue as a going concern. Additionally, Annovis Bio incurred severance expense related to the departure of its Chief Financial Officer in March 2026.
Key Highlights
- Net loss for Q1 2026 widened to $(17.6) million from $(5.5) million in Q1 2025.
- Research and development expenses increased 233% to $16.7 million in Q1 2026.
- Cash and cash equivalents decreased to $14.2 million as of March 31, 2026.
- Total liabilities significantly increased to $13.1 million from $4.2 million.
- Total stockholders' equity decreased to $3.1 million from $16.9 million.
- Management identified substantial doubt about the company's ability to continue as a going concern.
- The company incurred $0.1 million severance expense for its departing CFO in March 2026.
- Net cash used in operating activities increased to $(9.0) million from $(8.1) million.
Price Impact
More from ANVS